Kayne Anderson Rudnick Investment Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.7K | Sell |
|
|||||
|
2025
Q1 | $294M | Buy |
|
|||||
|
2024
Q4 | $333M | Sell |
|
|||||
|
2024
Q3 | $382M | Buy |
|
|||||
|
2024
Q2 | $394M | Buy |
|
|||||
|
2024
Q1 | $509M | Buy |
|
|||||
|
2023
Q4 | $414M | Buy |
|
|||||
|
2023
Q3 | $342M | Buy |
|
|||||
|
2023
Q2 | $353M | Buy |
|
|||||
|
2023
Q1 | $329M | Buy |
|
|||||
|
2022
Q4 | $352M | Sell |
|
|||||
|
2022
Q3 | $321M | Buy |
|
|||||
|
2022
Q2 | $344M | Sell |
|
|||||
|
2022
Q1 | $465M | Buy |
|
|||||
|
2021
Q4 | $585M | Buy |
|
|||||
|
2021
Q3 | $611M | Buy |
|
|||||
|
2021
Q2 | $517M | Buy |
|
|||||
|
2021
Q1 | $366M | Buy |
|
|||||
|
2020
Q4 | $273M | Buy |
|
|||||
|
2020
Q3 | $214M | Buy |
|
|||||
|
2020
Q2 | $138M | Buy |
|
|||||
|
2020
Q1 | $81.7M | Sell |
|
|||||
|
2019
Q4 | $185M | Buy |
|
|||||
|
2019
Q3 | $149M | Buy |
|
|||||
|
2019
Q2 | $65M | Buy |
|
|||||
|
2019
Q1 | $50.2M | Buy |
|
|||||
|
2018
Q4 | $34M | Sell |
|
|||||
|
2018
Q3 | $41.1M | Buy |
|